NCT03099980View on ClinicalTrials.gov

Exploratory Trial Evaluating Cosentyx (Secukinumab) for Patients With Moderate-to-Severe Hidradenitis Suppurativa

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 11, 2016

Primary Completion Date

December 31, 2018

Study Completion Date

January 31, 2019

Conditions
Hidradenitis Suppurativa
Interventions
BIOLOGICAL

secukinumab

secukinumab 300 mg (2 x 150 mg pre-filled syringe) administered at Baseline, Weeks 1, 2, 3, 4, and then Q4W for 24 weeks via subcutaneous injections

Trial Locations (1)

02111

Tufts Medical Center, Department of Dermatology, Boston

All Listed Sponsors
lead

Tufts Medical Center

OTHER

NCT03099980 - Exploratory Trial Evaluating Cosentyx (Secukinumab) for Patients With Moderate-to-Severe Hidradenitis Suppurativa | Biotech Hunter | Biotech Hunter